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OBJECTIVE — The aim of the study was to investigate whether serum lipopolysaccharide
(LPS) activities are associated with the progression of kidney disease in patients with type 1
diabetes.
RESEARCH DESIGN AND METHODS — For this prospective study, we chose 477
Finnish patients with type 1 diabetes, who were followed for 6 years. At the baseline visit, 239
patients had a normal albumin excretion rate (normoalbuminuria) and 238 patients had mac-
roalbuminuria.Patientswerefurtherdividedintononprogressorsandprogressorsbasedontheir
albumin excretion rate at follow-up. Eighty normoalbuminuric patients had developed mi-
croalbuminuria, and 79 macroalbuminuric patients had progressed to end-stage renal disease.
Serum LPS activity was determined with the Limulus amoebocyte lysate chromogenic end point
assay.
RESULTS — SerumLPSactivitywassigniﬁcantlyhigherinthemacroalbuminuricgroupthan
in the normoalbuminuric group (P  0.001). Notably, normoalbuminuric progressor patients
had a signiﬁcantly higher LPS activity at baseline than normoalbuminuric nonprogressor pa-
tients (median 49 [interquartile range 34–87] vs. 39 [29–54] EU/ml; P  0.001). The nor-
moalbuminuric progressor patients exhibited features of the metabolic syndrome with higher
triglyceride concentrations and lower estimated glucose disposal rate. A high LPS-to-HDL ratio
was associated with the progression of kidney disease in both groups. Insulin resistance (P 
0.001) and serum LPS activity (P  0.026) were independent risk factors of disease develop-
ment, when A1C was removed from the regression analysis.
CONCLUSIONS — High serum LPS activity is associated with the development of diabetic
nephropathy in Finnish patients with type 1 diabetes.
Diabetes Care 32:1689–1693, 2009
D
iabetic nephropathy is one of the
leading causes of death in patients
with type 1 diabetes worldwide. It
has been estimated that approximately
one-third of patients with type 1 diabetes
develop chronic kidney disease during
their lifetime (1). Patients with diabetic
nephropathy experience dyslipidemia
and macrovascular complications, which
inturnincreasestheriskofcardiovascular
death(2,3).Althoughrenaldysfunctionis
often associated with a long duration of
diabetes, poor glycemic control, and ge-
netic susceptibility, the etiology of the
complication is largely unknown. Recent
studies have demonstrated that patients
with type 1 diabetes have elevated levels
of proinﬂammatory markers in the serum
(4). It should also be noted that type 1
diabetic patients are more prone to infec-
tions than nondiabetic subjects (5).
Bacterial infections induce a systemic
inﬂammatory response, which may cause
severe organ damage or even death. Bac-
terial endotoxins/lipopolysaccharides
(LPSs) play a central role in acute and
chronic inﬂammations. LPS triggers the
innateimmuneresponsecharacterizedby
cytokine release and immune system ac-
tivation. LPS is a unique glycolipid lo-
cated at the outer membrane of Gram-
negative bacteria. These potentially
harmfulbacteriamaycolonizeindifferent
parts of the body including the oral mu-
cosa and gastrointestinal, genitourinary,
and respiratory tracts (6).
Bacterial infections may be life-
threatening,especiallyinpatientswhore-
quire dialysis or who have undergone
kidney transplantation. In such patients
with end-stage renal disease (ESRD), sep-
sis increases the risk of mortality 100-
fold compared with that for the general
population (7). Several studies have
shown that periodontitis is relatively
common among patients with diabetes
andimpairedkidneyfunction(8–10).Pe-
riodontitis refers to inﬂammation of the
supporting tissue of the teeth and is often
caused by Gram-negative bacteria. Bacte-
rial infections are also associated with
other forms of kidney disease, e.g., IgA
nephropathy, the most common form of
glomerulonephritis in the world (11). In
addition, bacterial endotoxins have been
commonly used to induce acute kidney
failure in laboratory animals. Given the
close association between periodontitis
and kidney disease on one hand and pe-
riodontitisandGram-negativebacteriaon
the other, it can be hypothesized that LPS
triggers not only inﬂammation in patients
with periodontitis but also the process
that leads to diabetic nephropathy. Thus,
we studied whether serum LPS activity is
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METHODS— Patients with type 1 di-
abetes were recruited and characterized
by the Finnish Diabetic Nephropathy
(FinnDiane) Study. The FinnDiane Study
is a nationwide multicenter survey, initi-
ated in 1997 to elucidate risk factors for
diabetic kidney disease in Finnish pa-
tientswithtype1diabetes.Thestudypro-
tocol is in accordance with the
Declaration of Helsinki, and it has been
approved by the local ethics committee at
each study center.
A total of 477 patients participated in
this study. Type 1 diabetes was deﬁned as
an age at onset 35 years and permanent
insulin treatment started within 1 year af-
ter the diagnosis. Data on medication and
smoking were collected with a standard-
ized questionnaire by the attending phy-
sician during the patient’s visit. Kidney
status was assessed by the albumin excre-
tion rate (AER) in at least two of three
overnight or 24-h urine collections: nor-
malalbuminexcretion(AER20g/min
or 30 mg/24 h), microalbuminuria
(AER 20  200 g/min or 30  300
mg/24-h), macroalbuminuria (200 g/
min or 300 mg/24 h), and ESRD (dial-
ysis treatment or kidney transplantation).
In addition to the urine collections for
classiﬁcation, AER (24 h) was also mea-
sured centrally; this result was used for
the statistical analysis. Patients with nor-
mal AER (normoalbuminuria) and mac-
roalbuminuriawereselectedforthestudy
based on their kidney status at the time of
reexamination. After the prospective fol-
low-up (5.9  2.1 years on average), all
available progressors, with a change from
one albuminuria category to a higher
level, were matched for sex and smoking
with a group of nonprogressors that was
twiceaslarge.Altogether239normoalbu-
minuric patients and 238 macroalbumin-
uric patients were included in this study.
Analysis of fasting blood samples
(A1C, serum lipids and lipoproteins,
and serum creatinine) were performed
as described earlier (12). Serum high-
sensitivity C-reactive protein concentra-
tions were measured centrally by
photometric immunochemistry at the
Helsinki University Central Hospital. Es-
timated glucose disposal rate (eGDR) was
calculated as described earlier (12). The
AER was measured centrally by photo-
metric immunochemistry at the Helsinki
University Central Hospital. Serum LPS
activity was determined with a Limulus
amoebocyte lysate chromogenic end
pointassayfrom1:5dilutedsamples(Hy-
cult Biotechnology, Uden, the Nether-
lands). HDL is one of the key factors
involved in the detoxiﬁcation of endotox-
ins and is known to decline with the se-
verity of diabetic nephropathy. The LPS-
to-HDL ratio may reﬂect the severity of
the condition. Serum IgA and IgG class
antibodies to the periodontal pathogens
Aggregatibacter actinomycetemcomitans
and Porphyromonas gingivalis were deter-




Data are expressed as means  SD for
normally distributed variables. For non-
normally distributed values, data are ex-
pressed as median (interquartile range
[IQR]). The levels of signiﬁcance were
tested with ANOVA for normally distrib-
uted values, and nonnormally distributed
values were analyzed with the Mann-
Whitney U test. Correlations between
clinical variables were analyzed by Pear-
son’s correlation coefﬁcient. Nonnor-
mally distributed variables were log
transformed for the analysis. Differences
between frequencies were tested with
Pearson’s 
2 test. The signiﬁcance of dis-
ease-associated variables was tested with
multivariate Cox regression analysis. Sta-
tistical analyses were performed with
SPSS (version 15.0; SPSS, Chicago, IL).
P  0.05 was considered statistically
signiﬁcant.
RESULTS— The principal aim of the
study was to investigate whether serum
LPS activity is associated with the pro-
gression of kidney disease in 477 patients
with type 1 diabetes. At the basal visit,
239 patients had a normal AER and 238
hadmacroalbuminuria.Clinicalcharac-
teristics of the patients are shown in
Table 1.
At baseline, macroalbuminuric pa-
tientshadsigniﬁcantlyhigherLPSactivity
(53 [IQR 38–74] vs. 42 [31–60] EU/ml,
P  0.001) than normoalbuminuric pa-
tients. LPS activity did not differ between
sexes among all patients. However, in the
normoalbuminuric group male patients
had slightly higher LPS activity than fe-
males(44[33–63]vs.38[29–52]EU/ml,
P  0.037).
In the normoalbuminuric group, 80
of 239 patients developed microalbumin-
uria during the follow-up. Clinical char-
acteristics of the normoalbuminuric
Table 1—Clinical characteristics of 477 type 1 diabetic patients at baseline
Normoalbuminuria Macroalbuminuria P
Subjects (men/women) 239 (150/89) 238 (149/89)
Age (years) 32  11 41  10 0.001
Age at onset (years) 16  91 1  7 0.001
Duration (years) 17  11 29  8 0.001
Follow-up (years) 6.2 (4.4–7.2) 6.8 (5.7–7.4) 0.001
BMI (kg/m
2) 24.7  3.3 25.8  4.1 0.001
Waist-to-hip ratio 0.86  0.08 0.90  0.09 0.001
A1C (%) 8.5  1.6 8.9  1.5 0.004
Diastolic blood pressure (mmHg) 79  98 3  10 0.001
Systolic blood pressure (mmHg) 128  15 144  20 0.001
Serum creatinine (mol/l) 84 (75–92) 132 (102–204) 0.001
Serum C-reactive protein (mg/l) 1.9 (1.2–3.6) 2.7 (1.6–5.4) 0.001
Cholesterol (mmol/l) 4.8  1.0 5.4  1.1 0.001
Triglycerides (mmol/l) 1.07 (0.80–1.44) 1.42 (1.03–2.09) 0.001
HDL cholesterol (mmol/l) 1.33  0.37 1.17  0.38 0.001
LDL cholesterol (mmol/l) 2.90  0.85 3.44  0.93 0.001
ApoAI (g/l) 138  20 140  24 NS
ApoAII (g/l) 35  83 4  7N S
ApoB (g/l) 88  20 103  23 0.001
AER (mg/24 h) 10 (7–17) 626 (225–1497) 0.001
eGDR (mg   kg
1   min
1) 7.4 (5.7–9.0) 4.1 (3.1–5.0) 0.001
Adiponectin (mg/l) 10.3 (7.2–13.7) 15.0 (10.4–22.3) 0.001
Antihypertension medication (%) 10 92 0.001
Lipid-lowering medication (%) 4 25 0.001
Current smoking (%) 32 32 NS
Data are expressed as means  SD or median (IQR).
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uric progressor patients are presented in
supplementary appendix 1 (available at
http://care.diabetesjournals.org/cgi/content/
full/dc09-0467/DC1). Groups were
matched for sex and smoking. At base-
line, there were no signiﬁcant differences
in antihypertensive (normoalbuminuric
nonprogressor 8.2% vs. normoalbumin-
uric progressor 12.7%) or lipid-lowering
(3.1 vs. 5.0%) medications between the
groups. The normoalbuminuric nonpro-
gressor patients had signiﬁcantly higher
A1C (9.4  1.7 vs. 8.0  1.4%, P 
0.001), total cholesterol (5.1  1.1 vs.
4.7  0.9 mmol/l, P  0.001), LDL cho-
lesterol (3.15  0.91 vs. 2.78  0.80
mmol/l,P0.002),apolipoprotein(apo)
B (94  21 vs. 85  19 g/l, P  0.001),
and triglyceride concentrations (1.11
[IQR 0.88–1.90] vs. 1.06 [0.79–1.33],
P  0.04), as well as AER (16.7 [9.7–
37.2]vs.8.3[5.9–12.3],P0.001)than
normoalbuminuric nonprogressor pa-
tients. Normoalbuminuric progressor pa-
tients were also more insulin resistant
(eGDR 6.5 [4.9–8.1] vs. 8.4 [6.1–9.3],
P  0.001). Of note, the normoalbumin-
uricprogressorpatientshadhigherserum
LPSactivitythannormoalbuminuricnon-
progressor patients (49 [34–87] vs. 39
[29–54] EU/ml, P  0.001). However,
serum antibody levels to the periodontal
pathogen A. actinomycetemcomitans were
not different between the groups. The
normoalbuminuric progressor patients
had slightly lower IgG levels to P. gingiva-
lis than normoalbuminuric nonprogres-
sor patients (Table 2).
In the normoalbuminuric group,
variables signiﬁcantly associated with
progression in univariate analysis (A1C,
LDL cholesterol, triglycerides, apoB,
eGDR, and LPS) were further tested in a
Cox regression model. The A1C (hazard
ratio 1.28 [95% CI 1.11–1.49], P 
0.001)andeGDR(0.89[0.80–1.00],P
0.044) were independent risk factors for
incident microalbuminuria (Table 3,
model 1). When A1C was removed from
themodel,botheGDR(0.83[0.75–0.91],
P  0.001) and lnLPS (1.85 [1.08–3.18],
P  0.026) were associated with disease
development (Table 3, model 2). Because
progression was deﬁned based on a
change in AER, it is natural that AER is a
strong predictor of disease progression.
Hence, we also included this variable into
the regression analyses. As expected, the
AER itself was the strongest predictor of
disease progression in all models (data
not shown).
Inthemacroalbuminuricgroup,79of
238 patients progressed to ESRD during
follow-up. Clinical characteristics of the
progressors and nonprogressors are pre-
sentedinsupplementaryappendix2.The
groups were matched for sex and smok-
ing. At baseline, macroalbuminuric pro-
gressor patients were treated more often
with lipid-lowering agents than the mac-
roalbuminuric nonprogressor patients
(37 vs. 20%, P  0.003). No differences
were seen in the frequency of antihyper-
tensive medication between the groups.
The macroalbuminuric progressor pa-
tients had higher A1C (9.3  1.8 vs.
8.7  1.3%, P  0.016), systolic blood
pressure (149  21 vs. 141  19 mmHg,
P  0.01), serum creatinine (275 [IQR
157–364] vs. 117 [94–139] mol/l; P 
0.001), serum triglyceride (1.71 [1.13–
2.63] vs. 1.27 [0.98–1.70 mmol/l], P 
0.001), and serum adiponectin levels
(20.4 [13.4–32.1] vs. 13.4 [9.0–19.6],
P  0.001) than macroalbuminuric non-
progressor patients. No difference in in-
sulin sensitivity (eGDR) was found
between the groups (P  0.118).
A high LPS-to-HDL ratio was associ-
ated with both the development of mi-
croalbuminuria and with the progression
of kidney disease (normoalbuminuric
nonprogressor 30 [IQR 21–43] vs. nor-
moalbuminuric progressor 39 [26–65],
P  0.001 and macroalbuminuric non-
progressor 47 [28–67] vs. macroalbu-
minuric progressor 57 [38–82], P 
0.017) (Fig. 1). At baseline, macroalbu-
minuric patients had higher serum levels
ofP.gingivalisIgAantibodies(0.81[0.37–
1.40] vs. 0.58 [0.32–0.91]; P  0.01)
than normoalbuminuric patients. The se-
rum levels of A. actinomycetemcomitans
IgG antibodies were also slightly lower in
the macroalbuminuric patients. In the
macroalbuminuric group, neither the se-
rum LPS activity nor IgA/IgG antibody




A1C (%) 1 1.28 (1.11–1.49) 0.001
eGDR (mg   kg
1   min
1) 1 0.89 (0.80–1.00) 0.044
ApoB (g/l) 1 0.99 (0.97–1.02) 0.646
LDL cholesterol (mmol/l) 1 1.31 (0.80–2.16) 0.282
ln(triglycerides) (mmol/l) 1 1.05 (0.49–2.22) 0.905
ln(LPS) (EU/ml) 1 1.51 (0.84–2.71) 0.17
eGDR (mg   kg
1   min
1) 2 0.83 (0.75–0.91) 0.001
ApoB (g/l) 2 1.00 (0.97–1.02) 0.865
LDL cholesterol (mmol/l) 2 1.21 (0.74–1.98) 0.447
ln(triglycerides) (mmol/l) 2 1.10 (0.52–2.34) 0.798
ln(LPS) (EU/ml) 2 1.85 (1.08–3.18) 0.026
Table 2—Serum LPS activity and antibody levels to periodontal pathogens
NA MA NA non NA prog MA non MA prog
n 239 238 159 80 159 79
LPS (EU/ml) 42 (31–60) 53 (38–74)‡ 39 (29–54) 49 (34–87)‡ 50 (35–75) 58 (44–73)
Aa IgA (EU) 1.07 (0.78–1.73) 1.15 (0.81–1.82) 1.04 (0.78–1.70) 1.17 (0.76–1.83) 1.15 (0.81–1.83) 1.15 (0.78–1.75)
Aa IgG (EU) 2.69 (1.94–3.92) 2.30 (1.61–3.47)† 2.70 (2.05–3.95) 2.65 (1.88–3.78) 2.44 (1.68–3.69) 2.07 (1.47–3.33)
Pg IgA (EU) 0.58 (0.32–0.91) 0.81 (0.37–1.40)† 0.56 (0.32–0.88) 0.58 (0.33–1.19) 0.79 (0.33–1.40) 0.85 (0.42–1.89)
Pg IgG (EU) 5.23 (4.25–6.13) 5.27 (4.26–7.05) 5.52 (4.25–6.29) 4.94 (4.24–5.87)* 5.39 (4.38–6.91) 5.12 (4.11–7.51)
*P  0.05; †P  0.01; ‡P  0.001. Aa, A. actinomecetemcomitans; MA, microalbuminuria; NA, normoalbuminuria; non, nonprogressors; Pg, P. gingivalis; prog,
progressors.
Nymark and Associates
DIABETES CARE, VOLUME 32, NUMBER 9, SEPTEMBER 2009 1691levels to periodontal pathogens were as-
sociated with the progression of kidney
disease (Table 2).
SerumLPSactivitywasrelatedtosev-
eral clinical variables. Among all patients,
the best correlations were observed be-
tween serum LPS activity and serum lip-
ids: ln(LPS) versus ln(triglycerides) (r 
0.61, P  0.001), ln(LPS) versus choles-
terol (r  0.34, P  0.001), ln(LPS) ver-
sus apoB (r  0.34, P  0.001), and
ln(LPS) versus HDL (r  0.24, P 
0.001) (supplementary appendix 3). Ad-
justment of serum LPS activity with HDL
concentrations strengthened the correla-
tion with serum triglyceride concentra-
tion [ln(LPS-to-HDL ratio) vs.
ln(triglycerides), r  0.68, P  0.001].
CONCLUSIONS — Diabetic ne-
phropathy is a devastating health condi-
tion that causes morbidity and mortality.
It has been estimated that approximately
one-third of the patients with type 1 dia-
betes develop diabetic nephropathy dur-
ing their lifetime. Although long duration
of diabetes and poor glycemic control are
associated with the progression of kidney
disease, it is evident that other yet-
unknown risk factors must exist.
Our living environment is inhabited
with viruses and microorganisms, of
which some are beneﬁcial and others are
detrimentaltohealth.Gram-negativebac-
teria are considered harmful pathogens,
which may colonize in various sites in the
human body. In chronic diseases in par-
ticular, bacterial infections may cause sig-
niﬁcant damage to health. Bacterial LPS
contributes to acute and chronic inﬂam-
mations and triggers the innate immune
response characterized by cytokine re-
lease and immune system activation.
We show here for the ﬁrst time that
high serum LPS activity is associated with
the development of microalbuminuria in
patients with type 1 diabetes. Although
macroalbuminuric patients had a signiﬁ-
cantlyhigherserumLPSactivitythannor-
moalbuminuric patients, those in the
macroalbuminuric group whose disease
progressed were no different from those
whose disease did not progress. There-
fore, other factors seem to play a more
important role in the disease progression
of macroalbuminuric patients.
LPS has been shown to be associated
with various classes of serum lipopro-
teins. In a normal situation, HDL is
thought to be the main factor involved in
the detoxiﬁcation/neutralization of LPS.
LPS is released from the cell membranes
by HDL and eventually cleared by the
liver (6). In certain disease conditions,
suchasatherosclerosis,periodontitis,and
bacterial sepsis, HDL levels can be signif-
icantly reduced. This may lead to LPS re-
distribution toward apoB-containing
LDL- and VLDL-rich particles (14–16).
In this respect it is understandable that
progression of kidney disease has been
linked to both dyslipidemia and meta-
bolic syndrome in patients with type 1
diabetes (2,12,17). Normoalbuminuric
patients who developed microalbumin-
uria displayed several features of the met-
abolic syndrome, including decreased
insulin sensitivity, dyslipidemia, and
poor glycemic control. Notably, serum
LPS activity showed a strong positive cor-
relation with serum triglyceride and apoB
concentrations. A concomitant decrease
in serum HDL concentrations could indi-
catethatLPSmoleculesaredistributedto-
ward apoB-containing VLDL/LDL
particles. We have recently demonstrated
that high LPS activity, especially in com-
bination with a low HDL cholesterol con-
centration increases the risk of incident
cardiovascular disease events in the
FINRISKstudy,asurveyonriskfactorsof
chronic diseases in the Finnish popula-
tion (13). Likewise in the present study, a
high LPS-to-HDL ratio was associated
withthedevelopmentofkidneydiseasein
normoalbuminuric patients and with
progression in macroalbuminuric pa-
tients with type 1 diabetes.
Serum LPS activity in itself does not
reveal the type or source of infection.
Based on previous ﬁndings, Gram-
negative bacterial infections are relatively
common in patients with periodontitis
and chronic kidney disease (8–10,18). In
the present study, we did not see an asso-
ciationbetweentwocommonperiodontal
pathogens (A. actinomycetemcomitans and
P. gingivalis) and the progression of the
kidney disease in patients with type 1 di-
abetes. This does not, however, rule out
detrimental effects of periodontal patho-
gens in patients with diabetic nephropa-
thy. It is also possible that harmful
bacterialpathogensmaycolonizeinother
parts of the body. Diabetic patients often
have respiratory tract infections. A recent
study demonstrates that poor glycemic
control and a long duration of type 1 di-
abetes increase the risk of pneumonia-
related hospitalization (19). The
gastrointestinal tract may also be inhab-
ited by pathogenic bacteria, e.g., Helico-
bacter pylori, which is one of the most
common causes of chronic infections in
humans (20). Recent studies have also
demonstrated that in mice fed a high-fat
diet, colonization of Gram-negative bac-
teria in their gut is increased. Changes in
gut microbiota may induce metabolic en-
dotoxemia, which is associated with in-
creased inﬂammation, obesity, and
insulin resistance (21,22). A high-fat diet
has also been shown to increase plasma
levels of bacterial endotoxins in humans
(23). A recent study in mice demon-
strated that long-chain fatty acids in par-
ticular promote LPS absorption from the
gut (24). Based on the above observa-
Figure 1—A high LPS-to-HDL ratio was associated with both the development of microalbumin-
uria in the normoalbuminuric (NA) group and with the progression of kidney disease in the
macroalbuminuria (MA) group. non, nonprogressors; prog, progressors.
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quality of lipids inﬂuence the transloca-
tion of LPS from the gastrointestinal tract
to the circulation. These results indicate
that infections in the gastrointestinal tract
mayalsocontributetothedevelopmentof
bacterialendotoxemiainhumans.Itisev-
ident that hyperglycemia increases the
risk for bacterial infections. In Danish di-
abetic patients, a 1 mmol/l increase in
plasma glucose was associated with a
6–10%increasedrelativeriskofpneumo-
nia, urinary tract infection, and skin in-
fection (25).
In the present study we showed that
poor glycemic control and high serum
LPS activity are associated with the devel-
opment of kidney disease in patients with
incidentmicroalbuminuria.Furtherstud-
ies are required to elucidate the role of
Gram-negative bacterial infections in pa-
tients with diabetes. In the future, identi-
ﬁcation of bacterial pathogens may help
us to ﬁnd more effective treatments for
thesepatients,whichmayalsoretardpro-
gression of diabetes complications.
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